Publication

Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates

Ong, K. J., Checchi, M., Burns, L., Pavitt, C., Postma, M. J. & Jit, M., Feb-2019, In : Sexually Transmitted Infections. 95, 1, p. 28-35 8 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Ong, K. J., Checchi, M., Burns, L., Pavitt, C., Postma, M. J., & Jit, M. (2019). Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Sexually Transmitted Infections, 95(1), 28-35. https://doi.org/10.1136/sextrans-2018-053606

Author

Ong, Koh Jun ; Checchi, Marta ; Burns, Lorna ; Pavitt, Charlotte ; Postma, Maarten J. ; Jit, Mark. / Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. In: Sexually Transmitted Infections. 2019 ; Vol. 95, No. 1. pp. 28-35.

Harvard

Ong, KJ, Checchi, M, Burns, L, Pavitt, C, Postma, MJ & Jit, M 2019, 'Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates', Sexually Transmitted Infections, vol. 95, no. 1, pp. 28-35. https://doi.org/10.1136/sextrans-2018-053606

Standard

Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. / Ong, Koh Jun; Checchi, Marta; Burns, Lorna; Pavitt, Charlotte; Postma, Maarten J.; Jit, Mark.

In: Sexually Transmitted Infections, Vol. 95, No. 1, 02.2019, p. 28-35.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Ong KJ, Checchi M, Burns L, Pavitt C, Postma MJ, Jit M. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Sexually Transmitted Infections. 2019 Feb;95(1):28-35. https://doi.org/10.1136/sextrans-2018-053606


BibTeX

@article{228d6c2d84d042798f6566fd808edcd5,
title = "Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates",
abstract = "Background: Many economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews. Methods: We conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider's perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016/2017 US$. Results: Sixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124-US$883 (anogenital warts), US$6912-US$52 579 (head and neck cancers), US$12 936-US$51 571 (anal cancer), US$17 524-34 258 (vaginal cancer), US$14 686-US$28 502 (vulvar cancer) and US$9975-US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper). Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95{\%} CI 0.85 to 0.87) and 0.74 (95{\%} CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95{\%} CI 0.0 to 0.76) to 0.94 (95{\%} CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95{\%} CI 0.4 to 0.61) to 0.65 (95{\%} CI 0.45 to 0.75) (anal cancer), 0.59 (95{\%} CI 0.54 to 0.64) (vaginal cancer), 0.65 (95{\%} CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95{\%} CI 0.74 to 0.84) (penile cancer). Conclusions: Differences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.",
keywords = "cost-effectiveness, HPV, meta-analysis, systematic reviews, vaccination, adult, anus cancer, article, cancer localization, cancer patient, cancer staging, case mix, condyloma acuminatum, cost effectiveness analysis, female, head and neck cancer, health care personnel, human, larynx papillomatosis, male, meta analysis, nonhuman, patient care, penis cancer, quality of life, synthesis, systematic review, vagina cancer, vulva cancer, Wart virus",
author = "Ong, {Koh Jun} and Marta Checchi and Lorna Burns and Charlotte Pavitt and Postma, {Maarten J.} and Mark Jit",
year = "2019",
month = "2",
doi = "10.1136/sextrans-2018-053606",
language = "English",
volume = "95",
pages = "28--35",
journal = "Sexually Transmitted Infections",
issn = "1368-4973",
publisher = "BMJ PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates

AU - Ong, Koh Jun

AU - Checchi, Marta

AU - Burns, Lorna

AU - Pavitt, Charlotte

AU - Postma, Maarten J.

AU - Jit, Mark

PY - 2019/2

Y1 - 2019/2

N2 - Background: Many economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews. Methods: We conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider's perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016/2017 US$. Results: Sixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124-US$883 (anogenital warts), US$6912-US$52 579 (head and neck cancers), US$12 936-US$51 571 (anal cancer), US$17 524-34 258 (vaginal cancer), US$14 686-US$28 502 (vulvar cancer) and US$9975-US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper). Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85 to 0.87) and 0.74 (95% CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95% CI 0.0 to 0.76) to 0.94 (95% CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95% CI 0.4 to 0.61) to 0.65 (95% CI 0.45 to 0.75) (anal cancer), 0.59 (95% CI 0.54 to 0.64) (vaginal cancer), 0.65 (95% CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95% CI 0.74 to 0.84) (penile cancer). Conclusions: Differences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.

AB - Background: Many economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews. Methods: We conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider's perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016/2017 US$. Results: Sixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124-US$883 (anogenital warts), US$6912-US$52 579 (head and neck cancers), US$12 936-US$51 571 (anal cancer), US$17 524-34 258 (vaginal cancer), US$14 686-US$28 502 (vulvar cancer) and US$9975-US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper). Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85 to 0.87) and 0.74 (95% CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95% CI 0.0 to 0.76) to 0.94 (95% CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95% CI 0.4 to 0.61) to 0.65 (95% CI 0.45 to 0.75) (anal cancer), 0.59 (95% CI 0.54 to 0.64) (vaginal cancer), 0.65 (95% CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95% CI 0.74 to 0.84) (penile cancer). Conclusions: Differences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.

KW - cost-effectiveness

KW - HPV

KW - meta-analysis

KW - systematic reviews

KW - vaccination

KW - adult

KW - anus cancer

KW - article

KW - cancer localization

KW - cancer patient

KW - cancer staging

KW - case mix

KW - condyloma acuminatum

KW - cost effectiveness analysis

KW - female

KW - head and neck cancer

KW - health care personnel

KW - human

KW - larynx papillomatosis

KW - male

KW - meta analysis

KW - nonhuman

KW - patient care

KW - penis cancer

KW - quality of life

KW - synthesis

KW - systematic review

KW - vagina cancer

KW - vulva cancer

KW - Wart virus

U2 - 10.1136/sextrans-2018-053606

DO - 10.1136/sextrans-2018-053606

M3 - Review article

VL - 95

SP - 28

EP - 35

JO - Sexually Transmitted Infections

JF - Sexually Transmitted Infections

SN - 1368-4973

IS - 1

ER -

ID: 92176231